AGM/EGMAug 4, 2026, 05:32 PM
Processa Pharma Shareholders Approve 200,000 Share Incentive Plan Increase
AI Summary
Processa Pharmaceuticals, Inc. held its 2026 Annual Meeting of Shareholders on July 30, 2026. Shareholders approved an amendment to the 2019 Omnibus Incentive Plan to increase the number of shares available for issuance by 200,000 shares. Additionally, shareholders elected six directors, ratified the appointment of Cherry Bekaert, LLP as the independent registered public accounting firm for 2026, and approved the advisory vote on executive compensation.
Key Highlights
- Shareholders approved an amendment to the 2019 Omnibus Incentive Plan, increasing available shares by 200,000.
- Six directors were elected to serve until the next Annual Meeting of Shareholders.
- The appointment of Cherry Bekaert, LLP as independent auditor for 2026 was ratified.
- The advisory vote relating to compensation of named executive officers was approved.
- Incentive Plan amendment received 579,877 'For' votes, 152,958 'Against', and 2,700 'Abstain'.
- Auditor ratification received 1,541,664 'For' votes, 12,770 'Against', and 6,389 'Abstain'.
- Advisory compensation vote received 640,726 'For' votes, 89,886 'Against', and 4,923 'Abstain'.
Price Impact
More from PCSA